PRECISE - pregabalin in addition to usual care for sciatica: study protocol for a randomised controlled trial

Trials

Chung-Wei Christine Lin⁵  Laurent Billot⁵  Stephen Jan⁵  Justin Pik²  Richard O Day³  Ian Harris⁷  Mark J Hancock⁴  Bart W Koes¹  Jane Latimer⁵  Andrew J McLachlan⁶  Christopher G Maher⁵  Stephanie Mathieson⁵ 

[1] Department of General Practice, Erasmus University Medical Center, Rotterdam, The Netherlands;ACT NeuroSpine Clinic, Australian Capital Territory, Deakin, Australia;St Vincent’s Clinical School, Faculty of Medicine, University of New South Wales, Sydney, Australia;Faculty of Human Sciences, Macquarie University, Sydney, Australia;The George Institute for Global Health and Sydney Medical School, University of Sydney, PO Box M201, Missenden Rd, Camperdown, Sydney, NSW 2050, Australia;Faculty of Pharmacy and Centre for Education and Research on Ageing, University of Sydney, Sydney, Australia;The South Western Sydney Clinical School, Faculty of Medicine, University of New South Wales, Sydney, Australia

关键词: Randomised control trial;    Neuropathic pain;    Pregabalin;    Sciatica;   

Others  :  1093435
DOI  :  10.1186/1745-6215-14-213

 received in 2013-05-24, accepted in 2013-07-01,  发布年份 2013

【 摘 要 】

Background

Sciatica is a type of neuropathic pain that is characterised by pain radiating into the leg. It is often accompanied by low back pain and neurological deficits in the lower limb. While this condition may cause significant suffering for the individual, the lack of evidence supporting effective treatments for sciatica makes clinical management difficult. Our objectives are to determine the efficacy of pregabalin on reducing leg pain intensity and its cost-effectiveness in patients with sciatica.

Methods/Design

PRECISE is a prospectively registered, double-blind, randomised placebo-controlled trial of pregabalin compared to placebo, in addition to usual care. Inclusion criteria include moderate to severe leg pain below the knee with evidence of nerve root/spinal nerve involvement. Participants will be randomised to receive either pregabalin with usual care (n = 102) or placebo with usual care (n = 102) for 8 weeks. The medicine dosage will be titrated up to the participant’s optimal dose, to a maximum 600 mg per day. Follow up consultations will monitor individual progress, tolerability and adverse events. Usual care, if deemed appropriate by the study doctor, may include a referral for physical or manual therapy and/or prescription of analgesic medication. Participants, doctors and researchers collecting participant data will be blinded to treatment allocation. Participants will be assessed at baseline and at weeks 2, 4, 8, 12, 26 and 52. The primary outcome will determine the efficacy of pregabalin in reducing leg pain intensity. Secondary outcomes will include back pain intensity, disability and quality of life. Data analysis will be blinded and by intention-to-treat. A parallel economic evaluation will be conducted from health sector and societal perspectives.

Discussion

This study will establish the efficacy of pregabalin in reducing leg pain intensity in patients with sciatica and provide important information regarding the effect of pregabalin treatment on disability and quality of life. The impact of this research may allow the future development of a cost-effective conservative treatment strategy for patients with sciatica.

Trial registration

ClinicalTrial.gov, ACTRN 12613000530729

【 授权许可】

   
2013 Mathieson et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Haanpää M, Treede RD: Diagnosis and classification of neuropathic pain epidemiology and impact of neuropathic pain. Pain Clinical Updates 2010, 18:1-6.
• [2]Smith BH, Torrance N: Epidemiology of neuropathic pain and its impact on quality of life. Curr Pain Headache Rep 2012, 16:191-198.
• [3]Attal N, Finnerup NB: Pharmacological management of neuropathic pain. Pain Clinical Updates 2010, 18:1-8.
• [4]Finnerup NB, Scholz J, Attal N, Baron R, Haanpää M, Hansson P, Raja SN, Rice ASC, Rief W, Rowbotham MC, Simpson DM, Treede RD: Neuropathic pain needs systematic classification. Eur J Pain 2013, 17:953-956.
• [5]Straube S, Derry S, McQuay HJ, Moore RA: Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. Brit J Clin Pharmacol 2008, 66:266-275.
• [6]McDermott AM, Toelle TR, Rowbotham DJ, Schaefer CP, Dukes EM: The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain 2006, 10:127-135.
• [7]Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, Portenoy RK, Rice ASC, Stacey BR, Treede RD, Turk DC, Wallace MS: Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007, 132:237-251.
• [8]Koes BW, Van Tulder MW, Peul WC: Diagnosis and treatment of sciatica. BMJ (Clinical research ed.) 2007, 334:1313-1317.
• [9]Konstantinou K, Dunn K: Sciatica: review of epidemiological studies and prevalence estimates. Spine 2008, 33:2464-24722.
• [10]Stafford MA, Peng P, Hill DA: Sciatica: a review of history, epidemiology, pathogenesis, and the role of epidural steroid injection in management. Brit J Anaesth 2007, 99:461-473.
• [11]Pinto RZ, Maher CG, Ferreira ML, Hancock M, Oliveira VC: Review epidural corticosteroid injections in the management of sciatica. Ann Intern Med 2012, 157:865-877.
• [12]Selim AJ, Ren XS, Fincke G, Deyo RA, Rogers W, Miller D, Linzer M, Kazis L: The importance of radiating leg pain in assessing health outcomes among patients with low back pain; results from the Veterans health study. Spine 1998, 15:470-474.
• [13]Lewis R, Williams N, Matar HE, Din N, Fitzsimmons D, Phillips C, Jones M, Sutton A, Burton K, Nafees S, Hendry M, Rickard I, Chakraverty R, Wilkinson C: The clinical effectiveness and cost-effectiveness of management strategies for sciatica: systematic review and economic model. Health Technol Assess 2011, 15:1-578.
• [14]Luijsterburg PAJ, Verhagen AP, Ostelo RWJG, Van Os TAG, Peul WC, Koes BW: Effectiveness of conservative treatments for the lumbosacral radicular syndrome: a systematic review. Eur Spine J 2007, 16:881-899.
• [15]Freynhagen R, Baron R: The evaluation of neuropathic components in low back pain. Curr Pain Headache Rep 2009, 13:185-190.
• [16]Pinto RZ, Maher CG, Ferreira ML, Ferreira PH, Hancock M, Oliveira VC, McLachlan AJ, Koes BW: Drugs for relief of pain in patients with sciatica: systematic review and meta-analysis. BMJ 2012, 344:E497-E497.
• [17]Peul WC, van den Hout WB, Brand R, Thomeer RTWM, Koes BW: Prolonged conservative care versus early surgery in patients with sciatica caused by lumbar disc herniation: two year results of a randomised controlled trial. BMJ (Clinical research ed.) 2008, 336:1355-1358.
• [18]Peul WC, van Houwelingen HC, van den Hout WB, Brand R, Eekhof JAH, Tans JTJ, Thomeer RTWM, Koes BW: Surgery versus prolonged conservative treatment for sciatica. N Eng J Med 2007, 356:2245-2256.
• [19]Ben-Menachem E: Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004, 45(Suppl 6):3-8.
• [20]Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ: Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009, Issue 3:CD007076.
• [21]Finnerup NB, Sindrup SH, Jensen TS: The evidence for pharmacological treatment of neuropathic pain. Pain 2010, 150:573-581.
• [22]Rosenstock J, Tuchman M, LaMoreaux L, Sharma U: Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004, 110:628-638.
• [23]Wiffen PJ, McQuay HJ, Edwards JE, Moore RA: Gabapentin for acute and chronic pain. Cochrane Database Syst Rev 2005., 3CD005452
• [24]Morlion B: Pharmacotherapy of low back pain: targeting nociceptive and neuropathic pain components. Curr Med Res Opin 2011, 27:11-33.
• [25]Romanò CL, Romanò D, Bonora C, Mineo G: Pregabalin, celecoxib, and their combination for treatment of chronic low-back pain. J Orthop Traumatol 2009, 10:185-191.
• [26]Flórez-García M, Ceberio-Balda F, Morera-Domínguez C, Masramón X, Pérez M: Effect of pregabalin in the treatment of refractory neck pain: cost and clinical evidence from medical practice in orthopedic surgery and rehabilitation clinics. Pain Pract 2011, 11:369-380.
• [27]Gordon J, Lister S, Prettyjohns M, McEwan P, Tetlow A, Gabriel Z: A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain. J Med Econ 2012, 15:207-218.
• [28]Baron R, Freynhagen R, Tölle TR, Cloutier C, Leon T, Murphy TK, Phillips K: The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. Pain 2010, 150:420-427.
• [29]Lampl C, Schweiger C, Haider B, Lechner A: Pregabalin as mono- or add-on therapy for patients with refractory chronic neuropathic pain: a post-marketing prescription-event monitoring study. J Neurol 2010, 257:1265-1273.
• [30]Toelle TR, Varvara R, Nimour M, Emir B, Brasser M: Pregabalin in neuropathic pain related to DPN, cancer and back pain: analysis of a 6-week observational study. Open Pain J 2012, 44:1-11.
• [31]Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher S: SPIRIT 2013 explanation and elaboration: guidance for protocols and clinical trials. BMJ 2013, 346:e7586.
• [32]Chou R, Qaseem A, Snow V, Casey D, Cross T, Shekelle P, Owens DK: Clinical guidelines diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med 2007, 147:478-491.
• [33]Koes BW, Tulder MWV, Ostelo R, Burton AK, Waddell G: An updated overview of clinical guidelines for the management of nonspecific low back pain in primary care. Eur Spine J 2010, 19:2075-2094.
• [34]Ehrlic GE: Low back pain. Bull World Health Organ 2003, 81:671-676.
• [35]Lyrica Approved Product information (Pregabalin) 2010:  . [https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04219-3 webcite]. Accessed March 2011
• [36]Williamson A, Hoggart B: Pain: a review of three commonly used pain rating scales. J Clin Nurs 2005, 14:798-804.
• [37]Brazier JE, Roberts J: The estimation of a preference-based measure of health from the SF-12. Med Care 2004, 42:851-859.
• [38]Kamper SJ, Ostelo RWJG, Knol DL, Maher CG, DeVet HCW, Hancock MJ: Global perceived effect scales provided reliable assessments of health transition in people with musculoskeletal disorders, but ratings are strongly influenced by current status. J Clin Epidemiol 2010, 63:760-766.
• [39]Freynhagen R, Baron R, Gockel U, Tölle TR: PainDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006, 22:1911-1920.
• [40]Kenward MG: Multiple imputation: current perspectives. Stat Methods Med Res 2007, 16:199-218.
• [41]Hintze J: PASS 2008, NCSS. Kaysville, Utah: LLC; 2008.
• [42]Ferriera ML, Herbert RD, Ferreira PH, Latimer J, Osteol RW, Nascimento DP, Smeets RJ: A critical review of methods used to determine the smallest worthwhile effect of interventions for low back pain. J Clin Epidemiol 2012, 65:253-261.
• [43]Dworkin RH, Turk DC, McDermott MP, Peirce-Sandner S, Burke LB, Cowan P, Farrar JT, Hertz S, Raja SN, Rappaport BA, Rauschkolb C, Sampaio C: Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain 2009, 146:238-244.
• [44]Williams CM, Latimer J, Maher CG, McLachlan AJ, Cooper CW, Hancock MJ, Day RO, McAuley JH, Lin CWC: PACE - The first placebo controlled trial of paracetamol for acute low back pain: design of a randomised controlled trial. BMC Musculoskel Dis 2010, 11:1-6. BioMed Central Full Text